Intact Fibroblast Growth Factor 23 Regulates Chronic Kidney Disease–Induced Myocardial Fibrosis by Activating the Sonic Hedgehog Signaling Pathway

Lanlan Li,Hua Gan
DOI: https://doi.org/10.1161/JAHA.122.026365
2022-09-15
Abstract:Background Clinically, myocardial fibrosis is one of the most common complications caused by chronic kidney disease (CKD). However, the potential mechanisms of CKD‐induced myocardial fibrosis have not been clarified. Methods and Results In our in vivo study, a rat model of CKD with 5/6 nephrectomy was established. The CKD model was treated with the glioma 1 (Gli‐1) inhibitor GANT‐61, and myocardial fibrosis and serum intact fibroblast growth factor 23 levels were assessed 16 weeks after nephrectomy. Finally, we found that Gli‐1 and Smoothened in the Sonic Hedgehog (Shh) signaling pathway were activated and that collagen‐1 and collagen‐3, which constitute the fibrotic index, were expressed in CKD myocardial tissue. After administering the Gli‐1 inhibitor GANT‐61, the degree of myocardial fibrosis was reduced, and Gli‐1 expression was also inhibited. We also measured blood pressure, cardiac biomarkers, and other indicators in rats and performed hematoxylin‐eosin staining of myocardial tissue. Furthermore, in vitro studies showed that intact fibroblast growth factor 23 promoted cardiac fibroblast proliferation and transdifferentiation into myofibroblasts by activating the Shh signaling pathway, thereby promoting cardiac fibrosis, as manifested by increased expression of the Shh, Patch 1, and Gli‐1 mRNAs and Shh, Smoothened, and Gli‐1 proteins in the Shh signaling pathway. The protein and mRNA levels of other fibrosis indicators, such as α‐smooth muscle actin, which are also markers of transdifferentiation, collagen‐1, and collagen‐3, were increased. Conclusions On the basis of these results, intact fibroblast growth factor 23 promotes CKD‐induced myocardial fibrosis by activating the Shh signaling pathway. Nonstandard Abbreviations and Acronyms 5/6NX 5/6 nephrectomy α‐SMA α‐smooth muscle actin ECM extracellular matrix FGF fibroblast growth factor Gli‐1 glioma 1 HRP horseradish peroxidase iFGF23 intact fibroblast growth factor 23 Npc1 niemann‐pick c1 PMF primary myocardial fibroblast Ptchd patched‐related protein SD Sprague‐Dawley Shh Sonic Hedgehog TGF transforming growth factor Clinical Perspective What Is New? GANT‐61 had no significant effect on the degree of myocardial hypertrophy and hypertension in the Sprague‐Dawley rat 5/6 nephrectomy model. GANT‐61 improved cardiac function and reduced cardiac weight by inhibiting myocardial fibrosis. Elevated serum levels of intact fibroblast growth factor 23 in chronic kidney disease model rats promoted the excessive proliferation of cardiac fibroblasts and their transdifferentiation into myofibroblasts, leading to the synthesis and secretion of a large amount of extracellular matrix proteins, thereby promoting cardiac fibrosis. What Are the Clinical Implications? As shown in the present study, ameliorating myocardial fibrosis in uremic cardiomyopathy improved cardiac function, providing some hope for clinically prolonging the life span of uremic patients. The Sonic Hedgehog signaling pathway and intact fibroblast growth factor 23 may be new therapeutic targets for delaying chronic kidney disease–induced cardiac fibrosis in the future. Chronic kidney disease (CKD) is a highly prevalent disease, with a prevalence of ≈12% in the global population. 1 Clinically, cardiovascular disease is one of the most important causes of death of patients with CKD on dialysis. 2 CKD is a well‐known independent cardiovascular risk factor. 3 Hypertension and cardiac hypertrophy are common in patients with CKD -Abstract Truncated-
What problem does this paper attempt to address?